Dynavax Technologies reported $583.91M in Current Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Adma Biologics ADMA:US $ 171.36M 5.92M
Agenus AGEN:US $ 92.85M 42.81M
Alexion Pharmaceuticals ALXN:US $ 6452.6M 619.6M
Amgen AMGN:US $ 19099M 2200M
AstraZeneca AZN:LN 27.27B 8.54B
Astrazeneca AZN:US 27.27B 8.54B
Biogen BIIB:US $ 7183.7M 464.2M
Biomarin Pharmaceutical BMRN:US $ 2357.84M 69.07M
BioSpecifics Technologies BSTC:US 102.07M 9.99M
Bristol Myers Squibb BMY:US $ 29161M 2050M
Chimerix CMRX:US 136.25M 11.89M
Dynavax Technologies DVAX:US $ 583.91M 156.37M
Gilead Sciences GILD:US $ 14498M 1220M
Glaxosmithkline GSK:US $ 17566M 958M
Gw Pharmaceuticals GWPH:US $ 718.73M 10.8M
Idera Pharmaceuticals IDRA:US $ 43.48M 3.54M
Minerva Neurosciences NERV:US $ 75.22M 6.46M
Nektar Therapeutics NKTR:US $ 1056.15M 42.9M
Neurocrine Biosciences NBIX:US $ 1110.1M 24.7M
Novartis NOVN:VX 23.81B 1.61B
Regeneron Pharmaceuticals REGN:US $ 13337.6M 3282.5M
Sarepta Therapeutics SRPT:US $ 2265.22M 6.13M
Vertex Pharmaceuticals VRTX:US $ 8457.51M 81.79M